drugset / Trial / NCT02628236

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

NCT02628236

Phase 2 Completed 14 enrolled DUSA Pharmaceuticals, Inc.
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.

Timeline

Start
2016-02
Primary completion
2016-05
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent 20 % Topical

Indications